Crispr Therapeutics AG (0VRQ) Share Forecast & Price Target
0VRQ Analyst Ratings
Moderate Buy
7Buy6Hold0Sell
Based on 13 analysts giving stock ratings to Crispr Therapeutics AG in the past 3 months
0VRQ Stock 12 Month Forecast
Average Price Target
$71.17▲(39.27% Upside)Based on 13 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is $71.17 with a high forecast of $110.00 and a low forecast of $45.00. The average price target represents a 39.27% change from the last price of $51.10.
Past 12 Months12 Month ForecastJan2026Oct2026
High$110.00
Average$71.17
Low$45.00
Highest Price TargetHighest$110.00Average Price Target$71.17Lowest Price TargetLowest$45.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Tyler Van Buren | TD Cowen | $45 | hold | -11.94%Downside | Reiterated | 10/21/26 | ||
| Joon Lee | UBS | $52 | hold | 1.76%Upside | Initiated | 10/15/26 | ||
| Mitchell Kapoor | H.C. Wainwright | $80 | buy | 56.56%Upside | Reiterated | 10/09/26 | ||
| Alec Stranahan | Bank of America Securities | $82→$81 | buy | 58.51%Upside | Reiterated | 10/09/26 | ||
| Gil Blum | Needham | $82 | buy | 60.47%Upside | Reiterated | 10/05/26 | ||
| Yanan Zhu | Wells Fargo | $75 | hold | 46.77%Upside | Reiterated | 10/02/26 | ||
| Yigal Nochomovitz | Citi | $88 | buy | 72.21%Upside | Reiterated | 09/04/26 | ||
| Jonathan Miller | Evercore ISI | $76 | buy | 48.73%Upside | Reiterated | 08/31/26 | ||
| Maxwell Skor | Morgan Stanley | $60 | hold | 17.42%Upside | Reiterated | 08/28/26 | ||
| Sami Corwin | William Blair | ― | buy | ― | Reiterated | 08/28/26 | ||
| Salveen Richter | Goldman Sachs | $48→$55 | hold | 7.63%Upside | Assigned | 08/10/26 | ||
| Edward Tenthoff | Piper Sandler | $110 | buy | 115.26%Upside | Reiterated | 08/04/26 | ||
| Luca Issi | RBC Capital | $50 | hold | -2.15%Downside | Reiterated | 08/03/26 | ||
| Silvan Turkcan | Citizens JMP | $80 | buy | 56.56%Upside | Reiterated | 07/22/26 | ||
 Unknown AnalystNot Ranked | Mizuho Securities | $85 | buy | 66.34%Upside | Reiterated | 06/10/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Tyler Van Buren | 10/21/26 | $45 | hold | -11.94%Downside | Reiterated | TD Cowen | ||
| Joon Lee | 10/15/26 | $52 | hold | 1.76%Upside | Initiated | UBS | ||
| Mitchell Kapoor | 10/09/26 | $80 | buy | 56.56%Upside | Reiterated | H.C. Wainwright | ||
| Alec Stranahan | 10/09/26 | $82→$81 | buy | 58.51%Upside | Reiterated | Bank of America Securities | ||
| Gil Blum | 10/05/26 | $82 | buy | 60.47%Upside | Reiterated | Needham | ||
| Yanan Zhu | 10/02/26 | $75 | hold | 46.77%Upside | Reiterated | Wells Fargo | ||
| Yigal Nochomovitz | 09/04/26 | $88 | buy | 72.21%Upside | Reiterated | Citi | ||
| Jonathan Miller | 08/31/26 | $76 | buy | 48.73%Upside | Reiterated | Evercore ISI | ||
| Maxwell Skor | 08/28/26 | $60 | hold | 17.42%Upside | Reiterated | Morgan Stanley | ||
| Sami Corwin | 08/28/26 | ― | buy | ― | Reiterated | William Blair | ||
| Salveen Richter | 08/10/26 | $48→$55 | hold | 7.63%Upside | Assigned | Goldman Sachs | ||
| Edward Tenthoff | 08/04/26 | $110 | buy | 115.26%Upside | Reiterated | Piper Sandler | ||
| Luca Issi | 08/03/26 | $50 | hold | -2.15%Downside | Reiterated | RBC Capital | ||
| Silvan Turkcan | 07/22/26 | $80 | buy | 56.56%Upside | Reiterated | Citizens JMP | ||
| Unknown AnalystNot Ranked | 06/10/26 | $85 | buy | 66.34%Upside | Reiterated | Mizuho Securities |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Crispr Therapeutics AG
3 Months
Success Rate19/36 ratings generated profit
53%
Average Return
+9.70%
Copying Geulah Livshits's trades and holding each position for 3 Months would result in 52.78% of your transactions generating a profit, with an average return of +9.70% per trade.
1 Year
Success Rate8/19 ratings generated profit
42%
Average Return
+8.13%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +8.13% per trade.
2 Years
Success Rate7/17 ratings generated profit
41%
Average Return
+1.04%
Copying Sami Corwin's trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of +1.04% per trade.
0VRQ Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 7 | 2 |
| Buy | 7 | 8 | 7 | 7 | 2 |
| Hold | 6 | 8 | 7 | 9 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 25 | 22 | 23 | 7 |
In the current month, 0VRQ has received 4 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0VRQ average Analyst price target in the past 3 months is 71.17.
0VRQ Financial Forecast
High$-0.46
Consensus$-1.04
Low$-1.51
0VRQ Earnings Forecast
Next quarter’s earnings estimate for 0VRQ is -$1.04 with a range of -$1.51 to -$0.46. The previous quarter’s EPS was -$0.94. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$77.3M
Consensus$14.8M
Low$0.00
0VRQ Sales Forecast
Next quarter’s sales forecast for 0VRQ is $14.75M with a range of $0 to $77.25M. The previous quarter’s sales results were $10.18M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0VRQ Stock Forecast FAQ
What is GB:0VRQ’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is $71.17.
What is GB:0VRQ’s upside potential, based on the analysts’ average price target?
Crispr Therapeutics AG has 39.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Crispr Therapeutics AG a Buy, Sell or Hold?
Crispr Therapeutics AG has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 6 hold ratings and 0 sell ratings.
What is Crispr Therapeutics AG’s share price target?
The average share price target for Crispr Therapeutics AG is $71.17. This is based on 13 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $110.00, and the lowest forecast is $45.00. The average share price target represents a 39.27% increase from the current price of $51.1.
What do analysts say about Crispr Therapeutics AG?
Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Street analysts.
How can I buy shares of Crispr Therapeutics AG?
To buy shares of GB:0VRQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.